interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Atorvastatin Calcium

Generic competition · all medicines · read 12 November 2026

Is there a generic of Atorvastatin Calcium, and who makes it?

Atorvastatin Calcium appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 20 generic makers listed as marketed across them. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. Where both are dated, the first generic approval came 15 years after the first brand approval. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Atorvastatin Calcium2 dosage-form groups in the Orange Book
20generic makers listed
  1. Atorvastatin Calcium appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 20 generic makers listed as marketed across them.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Where both are dated, the first generic approval came 15 years after the first brand approval.
  4. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Tablet, Oral

Four or more generic makers listed

Brand listed as marketed: Lipitor. 20 generic makers with 92 generic products listed as marketed; the first generic approval is dated 30 November 2011.

19952000200520102015202020252030020brand 1996Apotex Inc, first approval 29 May 2012Chartwell Rx Sciences Llc, first approval 29 May 2012Mylan Pharmaceuticals Inc, first approval 29 May 2012Dr Reddys Laboratories Ltd, first approval 17 July 2012Lannett Co Inc, first approval 5 April 2013Sciegen Pharmaceuticals Inc, first approval 19 May 2016Teva Pharmaceuticals Inc, first approval 27 March 2017Accord Healthcare Inc, first approval 30 March 2018Graviti Pharmaceuticals Private Ltd, first approval 18 June 2018Zydus Pharmaceuticals Usa Inc, first approval 20 November 2018Alkem Laboratories Ltd, first approval 21 December 2018Msn Laboratories Private Ltd, first approval 8 February 2019Umedica Laboratories Private Ltd, first approval 19 August 2020Biocon Pharma Ltd, first approval 23 November 2022Hetero Labs Ltd Unit V, first approval 12 September 2023Mankind Pharma Ltd, first approval 5 January 2024Laurus Labs Ltd, first approval 22 January 2024Shandong Xinhua Pharmaceutical Co Ltd, first approval 25 January 2024Aurobindo Pharma Ltd, first approval 13 February 2024Macleods Pharmaceuticals Ltd, first approval 3 June 2024data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Apotex Inc29 May 20128
Chartwell Rx Sciences Llc29 May 20124
Mylan Pharmaceuticals Inc29 May 20124
Dr Reddys Laboratories Ltd17 July 20128
Lannett Co Inc5 April 20134
Sciegen Pharmaceuticals Inc19 May 20164
Teva Pharmaceuticals Inc27 March 20178
Accord Healthcare Inc30 March 20184
Graviti Pharmaceuticals Private Ltd18 June 20184
Zydus Pharmaceuticals Usa Inc20 November 20184
Alkem Laboratories Ltd21 December 20184
Msn Laboratories Private Ltd8 February 20194

8 more makers are listed in the data.

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Suspension, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Atorvaliq. No generic is listed as marketed.

2020202520302035204001brand 2023data datePatent 11654106 listed to expire 7 June 2037Patent 11925704 listed to expire 7 June 2037Patent 12370136 listed to expire 7 June 2037Patent 12599553 listed to expire 7 June 2037Patent 12168069 listed to expire 7 June 2037Patent 11369567 listed to expire 7 June 2037
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 7 June 2037Patent 11654106 drug product
  • 7 June 2037Patent 11925704 drug product
  • 7 June 2037Patent 12370136 drug product
  • 7 June 2037Patent 12599553 drug product
  • 7 June 2037Patent 12168069 drug product
  • 7 June 2037Patent 11369567 drug product

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.